Education
About Us
Working with TipRanks
Follow Us
Rapport Therapeutics, Inc. (RAPP)
NASDAQ:RAPP
RAPP Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.43 - $29.74
Previous CloseN/A
Volume10.11K
Average Volume (3M)195.65K
Market Cap
$560.24M
Enterprise Value$154.32M
Total Cash (Recent Filing)$260.45M
Total Debt (Recent Filing)$11.86M
Price to Earnings (P/E)―
Beta1.41
Next Earnings
Nov 06, 2025EPS Estimate
-0.81Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.75
Shares Outstanding36,497,920
10 Day Avg. Volume275,167
30 Day Avg. Volume195,646
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.28
Enterprise Value/Revenue214.33
Enterprise Value/Gross Profit-1.13K
Enterprise Value/Ebitda-1.52
Forecast
1Y Price Target
$33.67Price Target Upside134.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe Phase IIa trial of RAP-219 in refractory focal epilepsy has completed enrollment with 30 patients and topline results are expected.
Commercial PotentialRAP-219 has potential to be best-in-class in refractory focal epilepsy due to its once daily dosing, no drug-drug interactions reported so far, and the safe and well tolerated profile observed in healthy patients.
Market InterestHigh interest exists in emerging clinical profiles for new epilepsy drugs, which could benefit Rapport Therapeutics.
Bears Say
Competitive LandscapeThe potential opportunity for RAP-219 exists, even if its clinical profile is not highly differentiated from FYCOMPA.
Drug CharacteristicsDr. Anschel expressed potential concern about the long half-life of RAP-219, which may affect how long it takes to reach a steady-state.
RAPP FAQ
What was Rapport Therapeutics, Inc.’s price range in the past 12 months?
Rapport Therapeutics, Inc. lowest stock price was $6.43 and its highest was $29.74 in the past 12 months.
What is Rapport Therapeutics, Inc.’s market cap?
Rapport Therapeutics, Inc.’s market cap is $560.24M.
When is Rapport Therapeutics, Inc.’s upcoming earnings report date?
Rapport Therapeutics, Inc.’s upcoming earnings report date is Nov 06, 2025 which is in 59 days.
How were Rapport Therapeutics, Inc.’s earnings last quarter?
Rapport Therapeutics, Inc. released its earnings results on Aug 07, 2025. The company reported -$0.75 earnings per share for the quarter, beating the consensus estimate of -$0.814 by $0.064.
Is Rapport Therapeutics, Inc. overvalued?
According to Wall Street analysts Rapport Therapeutics, Inc.’s price is currently Undervalued.
Does Rapport Therapeutics, Inc. pay dividends?
Rapport Therapeutics, Inc. does not currently pay dividends.
What is Rapport Therapeutics, Inc.’s EPS estimate?
Rapport Therapeutics, Inc.’s EPS estimate is -0.81.
How many shares outstanding does Rapport Therapeutics, Inc. have?
Rapport Therapeutics, Inc. has 36,497,920 shares outstanding.
What happened to Rapport Therapeutics, Inc.’s price movement after its last earnings report?
Rapport Therapeutics, Inc. reported an EPS of -$0.75 in its last earnings report, beating expectations of -$0.814. Following the earnings report the stock price went up 5.476%.
Which hedge fund is a major shareholder of Rapport Therapeutics, Inc.?
Currently, no hedge funds are holding shares in RAPP
Rapport Therapeutics, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$33.67 (134.47% Upside)
$33.67 (134.47% Upside)
Blogger Sentiment
Bullish
RAPP Sentiment 100%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Increased
By 684.4K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-32.32%
12-Months-Change
Fundamentals
Return on Equity
-29.42%
Trailing 12-Months
Asset Growth
-17.51%
Trailing 12-Months
Company Description
Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. The company also develops RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties; and nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and a9a10 nAChR for the treatment of hearing disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is based in Boston, Massachusetts.
RAPP Stock 12 Month Forecast
Average Price Target
$33.67
▲(134.47% Upside)
Technical Analysis
Ownership Overview
7.17% Insiders
24.17% Mutual Funds
0.03% Other Institutional Investors
63.22% Public Companies and
Individual Investors